Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
08 Febbraio 2024 - 10:05PM
Business Wire
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
biotechnology company with a robust pipeline of investigational
therapeutics built on protein dysregulation expertise, today
announced that it will report its fourth quarter and full year 2023
financial results on Thursday, February 15, 2024 after the close of
the U.S. financial markets. The announcement will be followed by a
live audio conference call at 4:30 PM ET.
The conference call will be made available on the Company's
website at www.prothena.com under the Investors tab in the Events
and Presentations section. Following the live audio webcast, a
replay will be available on the Company's website for at least 90
days.
To access the call via dial-in, please dial +1 (800) 715-9871
(U.S. and Canada toll free) or +1 (646) 307-1963 (international)
five minutes prior to the start time and refer to conference ID
number 1706941. A replay of the call will be available until
February 22, 2024, via dial-in at +1 (800) 770-2030 (U.S. and
Canada toll free) or +1 (609) 800-9909 (international), Conference
ID Number 1706941.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology
company with expertise in protein dysregulation and a pipeline of
investigational therapeutics with the potential to change the
course of devastating neurodegenerative and rare peripheral amyloid
diseases. Fueled by its deep scientific expertise built over
decades of research, Prothena is advancing a pipeline of
therapeutic candidates for a number of indications and novel
targets for which its ability to integrate scientific insights
around neurological dysfunction and the biology of misfolded
proteins can be leveraged. Prothena’s pipeline includes both
wholly-owned and partnered programs being developed for the
potential treatment of diseases including AL amyloidosis, ATTR
amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number
of other neurodegenerative diseases. For more information, please
visit the Company’s website at www.prothena.com and follow the
Company on Twitter @ProthenaCorp.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240208462325/en/
Investors Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com
Media Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
Grafico Azioni Prothena (NASDAQ:PRTA)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Prothena (NASDAQ:PRTA)
Storico
Da Gen 2024 a Gen 2025
